

Formulation And Evaluation of Mouth Dissolving Tablet of Moexipril with A Variety of Superdisintegrant and Compare with Market Moexipril Disintegration Tablet

Pooja Sharma¹, Praveen Kumar², Dr. Nasiruddin Ahmad Farooqui³

¹Student of Translam institute of Pharmaceutical Education and research center Meerut

^{2,3}Professor of Translam Institute of Pharmaceutical Education and research center Meerut

ABSTRACT

OBJECTIVE

The objective of the study is to formulate of mouth dissolving Tablet of Moexipril with a variety of super disintegrants and compare with marketed Moexipril disintegration tablet.

MATERIAL AND METHOD

The direct Compression method is used to Prepare mouth dissolving tablets of Moexipril utilizing super disintegrants Crospovidone and croscarmellose sodium. Determination of post compression study of formulated tablets Solidity, Thickness, Friability, medication content uniformity, weight variation, wetting time, Water absorption ratio, Dissolution time and Stability study of best preparation at $40^{\circ}\text{C}\pm 2/75\%\pm 5\% \text{RH}$ for 3 month.

RESULT AND DISCUSSION

In equipped Tablets device F7 very own dispersion time 13 sec, wetting time 46sec. short time period stability of method F7 has not any alternate change. in Physical appearance average weight, thickness, solidity, Friability, disintegration time in vitro dispersion time in vitro drug release at 10 min and assay stored for the three month at $40\pm 2^{\circ}\text{C}/75\%\pm 5\% \text{RH}$.

CONCLUSION

This study demonstrated that fast disintegrating moexipril tablets can be successfully formulated in order to control and manage hypertension.

Keywords: crospovidone croscarmellose sodium moexipril, oral dispersible tablet.

INTRODUCTION

Mouth Dissolving Tablets (MDT^s): These be the pills which melt and crumble unexpectedly inside the spit to produce their activities in a small number of seconds exclusive of the help of Distilled water. It takes over 15seconds-3minutes to mix into mouth for a mouth dissolving tablet. Primarily the MDT's (mouth dissolving tablets) have superb disintegrates and flavor masking agents.

For the administration of medication, the oral way was well thought-out the most frequently used way. Within it process, most normally used orally shipping of medicine, consisting of tablets and capsules.

Within this procedure consuming is the most difficulty. The swallowing problem (dysphasia) generally within the event of child's and olds patients believes mainly in compliance choose pills.

Toward solve this difficulty mouth dissolving tablets are formulated. For oral disintegration tablets preparation, the principal criterion is toward get rid of the sullenness of this drug by incorporating the sweeten mediator. Toward solve that difficulty and to create the dental route is more suitable for patients that very unique and latest method is using at present time which is known as oral dissolving drug delivery technique otherwise dispersible method. These mouth dissolving tablets break up or crumble unexpectedly inside the spit under a small number of seconds without needing liquid, chewing through the assist of spit in the oral.

The fantastic disintegrates additionally to raise the disintegration of tablets. Super dissolves are extremely cooperative to improve the drug release time of medication and raise the breakdown of pill within spit.

MATERIAL AND METHOD

Preparation of mouth dissolving tablets of Moexipril through direct compression process utilizing super disintegrates such as crospovidone and Croscarmellose sodium.

carry out the stability study of best preparation at $40^{\circ}\text{C} \pm 2 / 75\% \pm 5\% \text{RH}$ for 3months.

List of materials obtained from different andsources.


Drug profile:

Drug name: Moexipril

Moexipril an angiotensin converting enzyme inhibitor used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensive or diuretics. It works by inhibiting the conversion of angiotensin I to angiotensin II

Chemical Name: (3S)-2-[(2S)-2-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid.

Chemical structure:



Molecular Formula: C₂₇H₃₄N₂O₇

Physical characterization of Moexipril:

Melting point: Melting peak of Moexipril hydrochlorides were performing via the capillary system is 152°C . The documented melting point varies from 141°C to 161°C .

UV Spectroscopy (examination of λ_{max}) stock alternative ($100\text{-}10\mu\text{g/mol}$) of Moexipril is prepared in methanol. This mixture has been suitably mixed with methanol to obtain a concentration of $40\mu\text{g/mL}$. The solution was stored at a fused silica cuvette 10 mm. The UV spectrum has been listed in


the assortment of 200- 240 nm on UV-1800, Shimadzu double ray UV-visible spectrophotometer in 1 cm, sliced width.

Preparation of stock solution for calibration curve: Spectra-photometric method for estimation of Moexipril at Phosphate Buffer (pH 6.8). 100 mg of Moexipril was weighed, added with 50 ml volumetric flask disband in little amount of buffer and quantity was make using buffer to Acquire concentration of 1000 Mcg/ml. 5ml had been pipette outside and thin out to 50 ml with distilled water have the mass 100 mcg/ml. From this quantity was composed with HCl to acquire concentration of 4, 2, 8, 6, 10 mcg/ml. The absorbance was uniform at 238 nm utilizing Shimadzu-1800. Medication and excipients compatibility analysis by IR.

Table1 Standard calibration curve of Moexipril.

| Concentration in (µg/mL) | Absorbance at 248 (nm) |
|--------------------------|------------------------|
| 0 | 0 |
| 2 | 0.084 |
| 4 | 0.168 |
| 6 | 0.250 |
| 8 | 0.332 |
| 10 | 0.403 |
| Slopes | 0.042 |
| Correlations | 0.9995 |

Fig 1 Standard calibration curve of Moexipril phosphate buffer PH 6.8



All Pharmaceutical dosages form an essential element for recipients. It's an important Function in all pharmaceutical formula. The effective formulation relies on Fantastic choice of excipients. They encourage the constant launch and Bioavailability of medication.




Figure 2: Schematic representation of compatibility study.

Evaluations of mouth dissolving tablets Moexipril: Organoleptic properties:

Colour: Taken the small quantity of Moexipril on the butter paper and viewed the colour of the drug.

Taste and odor taken little small amount of drug and check the taste with the assist of tongue as well as smelled to odor.

Solubility test: check the dispersible of Moexipril in water, menthol and methyl alcohol by utilize ultrasonic at area temperature. About dispersible of drugs as pe B.P. shown in list

Drug and binding agent affinity studies: the drug and excipients mixed together and make a blend and stored at 40°C±2°C /75±5%RH with 30 days. The mass studies with every fifteen dayswithi change such as caking, liquefaction, discoloration and smell formulation.

FT-IR studies: any probability of chemical interactivity linking drug and excipients were evaluated by infrared spectra. Material combinations (2:2) of active and non-active are blend among an appropriate amount of potassium bromide. Concerning hundred milligram of that blend is condensed to form a visible pellet via a hydraulic force at ten plenty forces. Scan range 4000 – 5000 cm¹ within shimadzu FT-IR spectrophotometer.

Preformulation study:

The angle of Repose:

It is measured through funnel technique. Funnel is set on a flask stand at a specific peak . A chart wrapper is put under the funnel on a table. The crush is passing slowly across the funnel, until if form a pile. The blend powder is stop when the pile touches the tip of the funnel. Circumference of the pile of powder blend is drawn with the pencil without disturbing the pile. The radius of the pile ‘r’ is noted. the angle of repose was calculated using the following equation (table no. 2.7).

$$\tan \theta = h / r$$

Hence, $\theta = \tan^{-1} h/r$

Where, θ = angle of repose

h = height of the cone

r = radius of the cone base

The results are shown in ().

Table2: Relationship between the angle of repose (θ) and flow ability

| The Angle of Repose (θ) | Flow ability |
|----------------------------------|--------------|
| Less than 20 | Wonderful |
| 20 to 30 | Fine |
| 30 to 34 | Sufficient |
| More than 40 | Very poor |

The under the angle of repose, finer the move effects, when granules are placed in the hopper & allowed to slide down into the die for compression. It forms tablets. The angle of repose may be deliberate by determine the length (h) of the tablets and radius of the base (r) with the ruler. The angle of repose shows in between 30-40°C, which is considered as a passable flow of granules.

Application

Drug tablets, increase flow of granules from the hopper leads to under fill or overfills inside the die cavity. When a result, tablets will have under-weight or heavy weight; mass deviation again defected the homogeneity and doges accuracy. It too generates troubles of stability and friability throughout compression.

Bulk Density:

Mass density is the ratio of total mass of powder to the bulk volume of powder. It is evaluated via taken the weigh amount of blend crush beginning every preparation in a fifty ml test tube moreover the original quantity of the residue to calculate was written. The mass density of crush be obtained through the formula,(table no. 3.7)

$$P_b = M / V_b$$

Where.

ρ_b = mass density

m = Total mass of residue

v_b = mass volume of residue

Tapped density:

It is defined as whole mass of the dust is divided by tapped quantity of the dust. It is calculated by taken the grind in measuring cylinder and tapping the dust with seven thundered fifty count. The tapped level be marked. The difference b/w tow tapping less than two presents, if the difference > 2%, the tapping continued with 1250 times and the tapped volume is marked. The drumming regular when the difference b/w two tapping successive volume is less than 2%. It is calculated by the following formula, (table no. 3.7).

$$p_t = m / v_t$$

P_t = Tapped density

M = total mass of powder

V_t = tapped volume of powder

Compressibility Index:

The compressibility of the grind was calculated through Carr's Compressibility Index.

Carr's compressibility index (%) = [(TBD-LBD) X 100]/TBD

Or it can be expressed as Carr's Index relates the poured density of the material to the tapped density and was calculated by using the following relationship:

Compressibility Index = $\frac{\text{Tapped density} - \text{bulk density}}{\text{Density Tapped}} \times 100$

Carr's Index values for pure drug, crosspovidone, and granule be evaluated with measuring the primary volume (V_p) and finishing volume (V_t) of celebrated mass (W) of substance after introduce to hundred

pushing in a graduated test tube. Since this dimension, the poured density (W/Vp) and the tapped density (W/Vt) assessment were considered and were substitute within the above equation to evaluate Carr’s Index (Table 3.7).

Hausner’s ratio: this is the ratio of tapped density to bulk density. It is calculated by the following formula,

$$\text{Hausner's ratio} = \text{tapped density} / \text{bulk density.}$$

Table.3: Relationships b/w hausner ratio and flow properties.

| Hausner’sratio | Type of glide |
|----------------|---------------|
| > 1.25 | superior |
| 1.25-1.5 | Fair |
| < 1.5 | Pours |

Preparation of ODT^s through direct compression process:

Exactly weigh amount of Moexipril, crospovidone, Croscarmellose sodium, other ingredient and passed in 44 mesh sieves. The drug and microcrystalline cellulose be taken in a mortar and mixed and combine this, to produce a consistent combination and pigeonholed. After this procedure, the additional ingredient was variegated in symmetrical odour. Go across 44 mesh strainers. A tablet was press by a mechanical pressure. And the calibrated compacting forces of equipment to acquire solidity within range 3- 4 kg/cm² for total preparation. The mess of tablets of the formulation was 150 mg mention in (table 3).

Evaluations of post formulation studies of tablets: Psycho-Chemical studies of formulated tablets:

Thickness:

The thickness of tablets was determined through using venire caliper. There have been handiest five pills in every formula which are worn, and regular values existed measured. The thickness was denoted in millimeter. The result is proven in.

Test for the weigh variation:

To study weigh deviation 20 tablets was taken among each formulation and firstly individual tablet were weighed, after that total 20 tablets be weigh by an electronic balance (AW-220 shimadzu), the deviation not more than ± 7% and the experiment be carryout as maintained by bureaucrat system .

Table4: disclaimerfortabletsaspharmacopoeiaofIndia.

| The average weightof a Tablet | %Deviation |
|----------------------------------|------------|
| 80mg or below | Ten |
| Greater >80mg but below to 250mg | 7.5 |
| 250mg or> | 5 |

Drug content:

Four tablets were daintily crushed; quantity equivalent toward 50mg of Moexipril be appropriately weigh and shift to 100ml measurement piston containing 50ml of methanol. This becomes allowable

toward be set with six hours to make sure the whole solubility of the drugs. Answers had been making as much as quantity, strain, suitably diluted, and expected for Moexipril contents at 238 nm, the use of an UV spectrophotometer the usage of methanol as blank.

Hardness:

Every Chose the five tablets from every formulation, determine the hardness with Monsanto hardness tester (cadaman). The tablets were place beside its oblong axis inside between 2 jaws of tester on this peak; analysis must be 3-4 kg/cm². After that constant presser were appeal, noted the point at which tablets was breakup.

Friability:

It is measure of tablets strength. It is related to tablets ability to with stand both shook and abration with crumbling during the handling of manufacture, packing and consumer use.

Method: 6 tablets have been weighing and introduce inside Roche's friabilator wherever the tablets was showing to rolling at 25 rpm, and repeated shocks are resulting for free falls inside the equipment. After hundred revolutions, the pills were de-dusted and weight once more. The friability is known through the loss of percent of the weight of the tablet. Best less than 1 percent losses are relevant.

In-vitro* test of finished formulated tablets of Moexipril:*Determination of swelling index:**

The swelling index of drugs have been decided within phosphate buffer (pH 6.8), at room temperature till eight hours. Bloated burden of this tablet has been ascertained via as soon as intervals 15. The swelling equation may be determined without difficulty through using this equation:

$$\text{Percentage of water uptake polymer swelling} = \frac{(W_s - W_i)}{W_i} \times 100$$

Ws define the Wight of matrix at time t, W is the initial mass of the Matrix.

***In Vitro* drugRelease Studies (Dissolution study):**

In vitro drug release look at for the ready mold pills become performed with 10-12 hours the use of six station USP type II (paddle) equipment at 37°C ± 0.5 °C and 50 rpm speed. The disintegration analysis has been done in triplicate for 2 hours in phosphate buffer P^H 6.8. Eight under spout condition, first of all half an hour one hour after which in line with one hour length forms of 5ml was pulled from dissolving slight and substituted among a new mixture to hold the quantity continual. Right dilution is there at once afterward filtration, the pattern solution changed into analyzed at 248 nm for Moexipril by means of a UV-spectrophotometer for determining its cumulative % drug release or amount gift within the pattern (table no. 3.9).

Disintegration test

Dissolution time was considered with disintegration tests apparatus. Which have the six tube basket, the bottom surface of the basket was ready of stainless steel with steels screen (mesh no. #10). The tablets are placed in six tube of basket and distilled water was used as dissolution media. The test carries out at

37±0.5°C in disintegration equipment and the speed was 100 rpm. When the tablet was completely disintegrated, the time was noted. The disintegration time was expressed in second (table no. 3.8).

Data Analysis (Curve fitting analysis)

Toward decide the process of medicine release charge kinetics of pills and records acquired was plotted as:

The vs. of time and cumulative percentage of drug launch (*in vitro* drug launched plots). The vs of rectangular cause of times and drug release % (Higuchi, splots). The vs of time of the log cumulative percent drug remained (first-order plots). The vs. of time of the loge percent drug launch (Pappas plots).

Higuchi released model:

It represents the equation as,

$$F = K \cdot t_{1/2}$$

Whilst the facts are plots among cumulative drug release and the rectangular root of time. The direct line produces. It is indicated that the drug become launched by way of a dissemination process. The angle is identical near 'ok'90.

***In vitro* dispersion time:**

Take 10 ml of distilled water in a measuring cylinder. Five tablets were taken from each formulation and Tablets are added in distilled water at 37 ± 0.5°C. Determined the tablets for completes dispersion at time require (able no. 3.8).

Ratio of wetting time and absorption:

Taken 5 cm petridish. Two-piece of tissue paper is introduced to petridish. Water dissolve eosin pigment be put to petridish. The tablets are placed on the floor of tissue paper. After some time, the purple or pink shade is produced at the surface of tablet, the time is cited. It is a wetting time. The identical technique is accompanied by the water absorption ratio. It's far determined by using the subsequent equation,

$$R = \frac{W_b - W_a}{W_a} \times 100$$

$$W_a$$

Where,

$$W_b = \text{water absorption after wetting of tablets}$$

$$W_a = \text{Water absorption before wetting of tablets}$$

Stability studies:

The selected formulation became examined for three months at the storage conditions at room temperature and 40°C at 75% RH were inspect for their remedy content. The residual drug contents of formulations had been located to be in the permissible limits, as shown in the desk. The tablets showed excellent bodily stability at room temperature and forty °c at 75% RH. No appreciable changes were determined in any of the formulations. The drugs were additionally subjected to IR studies to determine well matched the drug with the recipients used within the pills. Their studies confirmed that no interactions between the active and polymers.

RESULTS AND DISCUSSION

Melting point: The melting point of Moexipril was found to be 184⁰C, which complies with given in the official reference.

FT-IR SPECTRAL STUDIES:




Fig.3: FTIR Spectra of Moexipril.

Evaluation of pre-compression parameters of all formulation

| Formulation | Angle of repose (θ) | Bulk density (g/cm ³) | Tapped density (g/cm ³) | Compressibility Index (%) | Hausner's ratio |
|----------------|----------------------|-----------------------------------|-------------------------------------|---------------------------|-----------------|
| F ₁ | 31 ⁰ .15' | 0.630 | 0.755 | 14.10 | 1.17 |
| F ₂ | 29 ⁰ .16' | 0.405 | 0.368 | 12.99 | 1.15 |
| F ₃ | 28 ⁰ .01' | 0.320 | 0.377 | 13.25 | 1.15 |
| F ₄ | 28 ⁰ .95' | 0.315 | 0.358 | 13.32 | 1.12 |
| F ₅ | 26 ⁰ .32' | 0.365 | 0.388 | 13.70 | 1.16 |
| F ₆ | 25 ⁰ .10' | 0.388 | 0.398 | 15.90 | 1.14 |
| F ₇ | 22 ⁰ .93' | 0.390 | 0.325 | 15.31 | 1.17 |

Table 5: FTIR spectral records of Moexipril.

| Wavenumber (cm ⁻¹) | Functional groups |
|--------------------------------|-------------------|
| 1580 | C=C |
| 2545 | O-H |
| 3450 | N-H |
| 1220 | C-O |
| 2950 | C-H |
| 1770 | C=O |




Fig.4 IR spectra of Croscarmellose sodium

Table 6 FTIR spectral statistics of Croscarmellose sodium.

| Wavenumber (cm ⁻¹) | Functional group |
|--------------------------------|------------------------|
| 3551 | OH stretch |
| 2932 | Aliphatics C-H stretch |
| 1649 | C=O stretch |
| 1090 | C-O stretch |
| 995 | CO-Cogroups |
| 713 | CH ₂ Alkane |

Table 7 Evaluation of physical properties of all formulation.

| Formulations | Thickness(mm) | Hardness(kg/cm ²) | Weight variant (mg) | Friability(%) |
|-----------------|---------------|-------------------------------|---------------------|---------------|
| F ₁ | 3.31±0.044 | 3.85 ± 0.35 | 143±1.22 | 0.25 |
| F ₂ | 3.35±0.012 | 4.16 ± 0.24 | 141±0.66 | 0.43 |
| F ₃ | 3.25±0.014 | 3.66 ± 0.32 | 141±0.45 | 0.51 |
| F ₄ | 3.41±0.012 | 4.18 ± 0.22 | 142±0.44 | 0.47 |
| F ₅ | 3.41±0.018 | 4.22 ± 0.44 | 143±0.97 | 0.33 |
| F ₆ | 3.22±0.055 | 3.60 ± 0.30 | 142±0.97 | 0.21 |
| F ₇ | 3.33±0.008 | 3.01 ± 0.25 | 140±0.46 | 0.16 |
| Marketed sample | 2.80±0.011 | 3.60 ± 0.32 Sec | €140±0.88 | 0.27 |

Table 8 Evaluation of tablets

| Formulations Codes | Disintegration Test (Sec) | Wetting Time () | Water Absorption Ratio | <i>In vitro</i> Dispersion Time (Sec) | Fineness of Dispersion |
|--------------------|---------------------------|------------------|------------------------|---------------------------------------|------------------------|
| F ₁ | 27±0.32 | 101±2.44 | 81.23±0.62 | 38±0.15 | Accepted |
| F ₂ | 23±0.22 | 91±1.45 | 86.37±0.48 | 39±0.13 | Accepted |
| F ₃ | 16±0.15 | 49±2.38 | 93.18±0.39 | 28±0.32 | Accepted |
| F ₄ | 23±0.50 | 87±0.81 | 78.26±0.20 | 38±0.16 | Passed |
| F ₅ | 24±0.62 | 80±0.20 | 88.13± 0.10 | 37±0.53 | Passed |
| F ₆ | 21±0.45 | 57±0.31 | 87.97±0.22 | 28±0.77 | Passed |
| F ₇ | 13±0.62 | 46±0.37 | 92.25±0.53 | 24±0.44 | Passed |
| Marketed Sample | 18±0.43 | 55±0.55 | 95.32±0.32 | 28±0.35 | Passed |

Table 9 Assay of Moexipril oral disintegration caplets.

| Formulation code | Limit (%) | Assay(%) |
|------------------|-----------|----------|
| F ₁ | | 99.62 |
| F ₂ | | 98.75 |
| F ₃ | | 99.82 |

| | | |
|-----------------|------------|-------|
| F ₄ | 90 to 110% | 99.62 |
| F ₅ | | 99.66 |
| F ₆ | | 98.92 |
| F ₇ | | 99.93 |
| Marketed sample | | 98.78 |

The assay of Moexipril mouth dissolving tablets were founded in the range between 98.75 to 99.93 %. According per IP acetabliits are 90 to 110 %, so the all formulation passed assay and have acceptable limits as per IP.

IN-VITRO DISSOLUTION DTUDIES:

Table10 : drug release percentage of Moexipril ODT^s:

| Times (min) | Drug release (%) | | | | | | |
|-------------|------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| | Formulation code | | | | | | |
| | F ₁ | F ₂ | F ₃ | F ₄ | F ₅ | F ₆ | F ₇ |
| 2 | 21.60±0.50 | 25.86±0.38 | 31.50±0.23 | 18.52±0.31 | 22.44±0.29 | 30.11±0.60 | 35.31±1.20 |
| 4 | 31.24±0.69 | 34.75±0.59 | 42.59±0.56 | 31.18±0.30 | 31.55±0.50 | 48.51±0.49 | 54.16±0.60 |
| 6 | 42.59±0.60 | 49.90±0.27 | 61.55±0.19 | 48.66±0.42 | 46.63±0.07 | 59.91±0.42 | 72.29±0.23 |
| 8 | 66.99±1.24 | 69.62±0.58 | 79.55±0.45 | 58.95±0.69 | 62.80±0.30 | 74.18±0.68 | 85.62±0.53 |
| 10 | 72.29±0.15 | 76.29±0.49 | 84.45±0.10 | 70.71±0.59 | 73.19±0.08 | 81.61±0.10 | 99.86±0.08 |

Fig5.In-vitro release studies of batch F₁ in pH 6.8 buffer




Fig6.In-vitro release studies of batch F₂ in pH 6.8 buffer




Fig 7. In-vitro release studies of batch F₃ in pH 6.8 buffer




Fig 8. In-vitro release studies of batch F₄ in pH 6.8 buffer




Fig. 9 In-vitro release studies of batch F₅ in pH 6.8 buffer




Fig.10 In-vitro release studies of batch F₆ in pH 6.8 buffer





Fig.11 In-vitro release studies of batch F₇ in pH 6.8 buffer



The formulation F₁, F₂, F₃ has the drug release 72.29 ± 0.15 , 76.29 ± 0.49 , 84.45 ± 0.10 respectively at ten min. The drug release (%) of formula F₄, F₅ and F₆ was found to be 70.71 ± 0.59 , 73.19 ± 0.08 , and 81.61 ± 0.10 at ten min. The formulation F₇ has drug release 99.86 ± 0.08 at ten min. expectable *invitro* melt curb was NLT80% of remedy discharge at ten min. So the formulation F₃, F₆ and F₇ passed in the in vitro dissolution test.

Table11 : Comparative dissolution studies of formulated formulation F₇ and marketed tablet.

| Time(min) | drug release (%) | |
|-----------|------------------|-----------------|
| | Formulation code | |
| | F ₇ | Marketed sample |
| 2.0 | 36.31±1.20 | 21.30± 0.27 |
| 4.0 | 53.16±0.60 | 33.18± 1.03 |
| 6.0 | 73.29±0.23 | 55.59± 0.95 |
| 8.0 | 84.62±0.53 | 71.60± 0.49 |
| 10.0 | 99.86±0.08 | 83.53± 0.44 |




Fig.12: Relative studies of invitro drug release data of Moexipril as well as marketed sample.

The drugs release% of marketed drug and formulated preparation F₇ be originate to 83.53± .44 and 99.86±0.08. so it is prove that the formulated formulation F₇ have best drug release percentage according to marketed sample.

Stability studies: The formulated formulation F₇ be selected for stability studies, store at 40±2⁰C/75%±5% RH for three month of period. The tablets are examined for following boundary as such, physical appearance, weight variation, thickness, hardness, disintegration time, excellence of dispersion, dissolution and assess. by each months gap for three month. The result be so within table 3.12.

Table12 :solidity statistics of Moexipril oral disintegration tablets keep at 40±2⁰C/75%±5% RH.

| S.NO. | Storage conditions: 40±2 ⁰ C/75%±5% RH | | | | |
|-------|---|-----------------|------------|------------|------------|
| | Test | original period | 30 days | 60 days | 90 days |
| 1 | Physical appearance | Not change | Not change | Not change | Not change |
| 2 | Weight variation | 142.49 | 141.99 | 142.29 | 141.30 |
| 3 | Thickness (mm) | 3.33 | 3.38 | 3.33 | 3.32 |
| 4 | Hardness (kg/cm ¹) | 3.01 | 3.1 | 3.01 | 3.01 |
| 5 | Friability (%) | 0.16 | 0.21 | 0.18 | 0.20 |
| 6 | Disintegration test (sec) | 11 | 11 | 9 | 07 |

| | | | | | |
|----|---|-------|-------|-------|-------|
| 7 | In vitro dispersion time (sec) | 23 | 23 | 23 | 22 |
| 8 | excellence of dispersion | Good | Good | Good | Good |
| 9 | <i>Invitro</i> drug release at the end of ten min (%) | 99.86 | 99.76 | 99.74 | 99.73 |
| 10 | Assess (Limit 99-110%) | 99.93 | 99.88 | 99.82 | 99.80 |

On the bases of above stability studies its observed that no significance change were found in physical appearance, weight variation, thickness, solidity, friability, disintegration test, *in vitro* disintegration period, excellence of collapse, *invitro* drug release with ten min and assess, stored for the 3 months at $40\pm 2^{\circ}\text{C}/75\%\pm 5\% \text{RH}$.

Conclusion

According to the previous work, Oro-dispersible tablets of Moexipril were invented with superb disintegrates such as croscopovidone, Croscarmellose sodium independently and also mix together, tablet are prepared by direct compression technique. Moexipril is a water-soluble drug but has limited bioavailability. Bioavailability of medication is raised via this method.

Super disintegrates such as croscopovidone and Croscarmellose sodium and blends reduce the dispersion period of tablets.

REFERENCES

1. Shukla Dali, Chakraborty Subhashis, Singh Sanjay, Misra Brahmeshwar, "Mouth Dissolving Tablet 1: An Overview of Formulation Technology", Journal of Scientia Pharmaceutica; 77: 2009: 309–327.
2. Lachman, Liberman HA, Anig JL. Theory and practice of industrial pharmacy. 3rd ed. Mumbai: Varghese Publishing House; 1991. p. 296-302.
3. Singh Sruti Gupta, Pal Singh Ravindra, Kumar Gupta Shivjee, KalyanwatRenu, YadavSudhir "Sciences, Buccal Mucosa as a route for Drug Delivery: Mechanism, Design and Evaluation", Research Journal of Pharmaceutical, Biological and Chemical, Science. Vol 2 (3); 2011:361-378.
4. Rathod Hemant, Shekhawat Shakti, Shah Jimit, Gandhi Parth "An Overview: Melt-In-Mouth Tablets" <http://www.pharmatutor.org/articles>.
5. PanigrahiRajeshree, BeheraSaiprasanna, A review on fast dissolving tablets, Webmed Central <http://www.webmedcentral.com> Article ID: WMC00809.
6. Kumar V. Dinesh, Sharma Ira, Sharma Vipin, A comprehensive review on fast dissolving tablet technology, Journal of Applied Pharmaceutical Science 01(05), 2011, 50-58.
7. JayantilalWadherKamlesh, BaliramKakdeRajendra, JanraoUmekarMilind, "Formulations of sustained release metformin hydrochloride tablet using combination of lipophilic waxes by melt granulation technique", African Journal of Pharmacy and Pharmacology 4(8) 2010, 555-561.
8. Devi Mutur, Jekku Naga, Reddy Subba "Design and characterization of melt-in-mouth tablets of metoprolol tartrate" International Journal of Pharmacy and Life Science, Vol 4(4) 2013:2608-2614.
9. AmishAshvinkumarDangi "Formulation and Evaluation of Carvedilol –Loaded Melt in Mouth" International Journal of Pharmaceutical Investigation Vol 2,(4): 2012 :183-188.

- 10 Mangukia Dhruv K., Asija Rajesh, Patel Chirag, Yadav Alpesh, Shah Isha, Sojitra Ishitra "Formulation and evaluation of melt in mouth tablets of Ondansetron" Research Journal of Pharmacy and Technology, Vol 5(8) year (2012) Page 1089-1092.
- 11 Subhakanta Kanungo¹, Saikh Mohammed Aghar Ali, Amalesh Samanta, Saikh Mohammed Athar Ali "Crosslink Polyacrylic Resin Based Levocetirizine Melt-In-Mouth Tablets" International Journal of Pharma Sciences and Research (IJPSR), Vol.2 (11), 2011, 196-204.
- 12 CSR Lakshmi, Sagar Pravin Akul, Totala Anup Vijay, Jitesh Chaudhary, Jagdish, Patel Nitesh Jagdish bhai, Vedhavati S.V. "Development and Characterization of Melt-In-Mouth Tablets of Atenolol By Sublimation Technique" International Journal Of Pharmaceutical Research And Development Volume 3,(3) :2011.
- 13 Kolhe S.R, Chaudhari P.D; More D.M "Development and Evaluation of Melt-In-Mouth Tablets by Sublimation Technique "International Journal of Pharmaceutical Studies and Research Vol. 2,(I): 2011:65-76
- 14 sn Satish Kumar P., Mehta Dharmini C., Shah Sejal P., Singh Pirthi Pal, and Amin Purnima D. "Melt-in-Mouth Pellets of Fexofenadine Hydrochloride Using Croscopovidone as an Spheronisation Aid" AAPS Pharm Sci Tech. Vol 11 (2):2010:917-923.
- 15 Kumar Ravi, Patil M.B., Patil, Sachin R., Paschapur, Mahesh S. "Development and characterization of melt-in-mouth tablets of Haloperidol by sublimation technique, "International Journal of Pharmacy and Pharmaceutical Sciences 1(1), 2009.